- Select the ESA agent — Epoetin alfa or beta (units/week), Darbepoetin alfa (mcg/week), or CERA / methoxy PEG-epoetin beta (Mircera, mcg/month).
- Enter the current hemoglobin (g/dL) from today's labs.
- Enter the Hgb change over the last 2–4 weeks (negative if falling; e.g., −0.5 if Hgb dropped 0.5 g/dL).
- Enter the current ESA dose in the units appropriate to the selected agent.
- Read the color-coded action and suggested new dose. Apply clinical judgment — unit protocols vary.
All computation runs in your browser; no values are stored or transmitted.
When to Use
Use this calculator when managing erythropoiesis-stimulating agent (ESA) therapy in adults with CKD anemia — including non-dialysis CKD, hemodialysis, and peritoneal dialysis patients — who are already on an ESA and require a dose check at a scheduled monitoring visit. The algorithm reflects KDIGO 2012 Anemia in CKD guidelines and FDA ESA REMS labeling.
Appropriate population
Adults with CKD anemia (any stage, including dialysis) already receiving Epoetin alfa or Darbepoetin alfa, with a current steady-state Hgb and a reliable 2–4 week Hgb trend. Before using ESAs, confirm iron stores are adequate (TSAT ≥20%, ferritin ≥200 ng/mL in HD) and non-renal causes of anemia have been excluded.
When NOT to rely on it alone
This dose-adjustment tool is for patients already on an ESA — for ESA-naïve patients, use the ESA Initiation Calculator below. Do not rely on it during acute illness or active infection (which can suppress ESA response), in the setting of uncorrected iron deficiency, or when hemoglobin is acutely changing due to blood loss or transfusion. ESA hyporesponsiveness requires clinical evaluation beyond a dose adjustment. Individual institution protocols and formulary availability may differ — always confirm with local prescribing guidelines.
Pearls & Pitfalls
Target Hgb 10–11.5 g/dL — never intentionally exceed 13 g/dL
KDIGO recommends maintaining Hgb between 10 and 11.5 g/dL to balance symptom relief against cardiovascular risk. The TREAT and CHOIR trials demonstrated excess cardiovascular events when targeting Hgb >13 g/dL. Hold ESA and do not resume at full dose if Hgb exceeds 11.5 g/dL.
Rate of rise matters — not just the absolute Hgb
A rapid rise (>1 g/dL over ~2 weeks or >2 g/dL/month) is an independent indication to reduce the dose by ~25%, regardless of whether the absolute Hgb is within the target band. Rapid rise predicts overshoot above 11.5 g/dL and increased cardiovascular risk.
Pitfalls and guardrails
- Do not increase the dose more often than every 4 weeks — less-frequent adjustments allow the Hgb response to fully manifest before the next change.
- If there is no Hgb response after a 25% dose increase, evaluate for ESA hyporesponsiveness: iron deficiency (most common), active infection or inflammation, hyperparathyroidism (PTH >500 pg/mL in HD), aluminum toxicity, or occult blood loss.
- Epoetin alfa/beta are typically dosed 1–3×/week (HD); darbepoetin alfa weekly or every 2 weeks; CERA (Mircera) has a long half-life (~130 h) and is usually given every 2–4 weeks or monthly. Convert your per-visit dose to the displayed unit (weekly for epoetin/darbepoetin, monthly for CERA); titrate longer-acting agents (darbepoetin, CERA) less frequently and more cautiously.
- Unit protocols vary widely — this output is a guide, not a standing order. Physician confirmation is required.
ESA / EPO Dose Adjustment Calculator — CKD Anemia
Enter the ESA agent, current Hgb, the 2–4 week Hgb change, and the current weekly dose. The calculator applies the KDIGO 2012 / FDA ESA labeling algorithm to recommend Hold, Reduce, Maintain, or Increase, and shows the suggested new weekly dose. Unit protocols vary — physician judgment is required.
⚕ Based on KDIGO 2012 Anemia in CKD guidelines and FDA ESA REMS labeling. Target Hgb: 10–11.5 g/dL. Do not intentionally target Hgb >11.5 g/dL. Do not increase dose more frequently than every 4 weeks. Unit protocols vary — physician confirmation and individualized assessment are required.
ESA Initiation Calculator — ESA-Naïve Patients
For patients not yet on an ESA. Enter the agent, body weight, current Hgb, and dialysis status to get the weight-based starting dose and schedule per FDA / EMA labeling for epoetin alfa, epoetin beta, darbepoetin alfa, and CERA (methoxy PEG-epoetin beta) and KDIGO 2012. An ESA is generally started only when Hgb is below 10 g/dL and after iron deficiency and other reversible causes have been addressed.
⚕ Starting doses follow FDA / EMA ESA labeling and KDIGO 2012. Epoetin alfa: 50 units/kg per dose, 3×/week (label range 50–100). Epoetin beta: 20 units/kg per dose, 3×/week SC. Darbepoetin alfa: 0.45 mcg/kg — once weekly on dialysis, every 4 weeks if not on dialysis (0.75 mcg/kg every 2 weeks is a labeled alternative). CERA (methoxy PEG-epoetin beta): 0.6 mcg/kg once every 2 weeks, switching to twice that dose once monthly when stable. Round to available vial strengths. Confirm iron repletion before the first dose. Physician confirmation and individualized assessment are required.
Next Steps
Use the result to support — not replace — clinical judgment.
- Recheck Hgb every 2–4 weeks during dose adjustment; every 1–3 months once stable on a maintenance dose.
- Before each ESA review, ensure iron stores are adequate (TSAT ≥20%, ferritin ≥200 ng/mL in HD) — iron deficiency is the commonest cause of ESA hyporesponsiveness.
- If no Hgb response after a 25% dose increase over 4–8 weeks, perform a formal hyporesponsiveness workup: iron panel, CRP/ESR, PTH, reticulocyte count, blood loss screen.
- Document the indication (target Hgb, clinical context) and the dose decision in the clinical record per ESA REMS requirements.
- Discuss the benefit-risk balance of ESA therapy with the patient, especially cardiovascular risk at higher Hgb targets.
Evidence & References
Algorithm Logic
| Hgb / Trend Condition | Action | Dose Change |
|---|---|---|
| Hgb >11.5 g/dL (any trend) | HOLD ESA | Stop; resume at ~25% reduction once Hgb <11 g/dL |
| Rapid rise: >1 g/dL in ~2 wk or >2 g/dL/month | REDUCE ~25% | Applies regardless of absolute Hgb; prevents overshoot |
| Hgb 11.0–11.5 g/dL AND rising | REDUCE ~25% | Approaching upper limit — preemptive reduction |
| Hgb 11.0–11.5 g/dL AND stable or falling | MAINTAIN | Observe; recheck in 2–4 weeks |
| Hgb 10–11 g/dL (in target) | MAINTAIN | Fine-tune if needed; stable dose preferred |
| Hgb <10 g/dL AND rising appropriately (≥+0.5 g/dL) | CONTINUE / RECHECK | ESA is working; continue current dose; recheck |
| Hgb <10 g/dL AND stable or falling | INCREASE ~25% | Do not increase more often than every 4 weeks |
| Rapid fall: Hgb fell >1 g/dL | INCREASE ~25% + evaluate | Investigate blood loss / hyporesponsiveness |
All dose changes are approximate (~25%). Unit protocols vary — physician confirmation is required. Never intentionally target Hgb >11.5 g/dL or >13 g/dL.
Initiation Logic (ESA-Naïve)
| Condition | Decision | Starting Dose |
|---|---|---|
| Hgb ≥ 10 g/dL | DEFER | Do not routinely start; correct iron deficiency and reversible causes first |
| Hgb < 10 g/dL · Epoetin alfa | INITIATE | 50 units/kg per dose, 3×/week (label range 50–100) |
| Hgb < 10 g/dL · Epoetin beta | INITIATE | 20 units/kg per dose, 3×/week SC |
| Hgb < 10 g/dL · Darbepoetin · on dialysis | INITIATE | 0.45 mcg/kg once weekly |
| Hgb < 10 g/dL · Darbepoetin · not on dialysis | INITIATE | 0.45 mcg/kg every 4 weeks (0.75 mcg/kg q2wk alternative) |
| Hgb < 10 g/dL · CERA (methoxy PEG-epoetin beta) | INITIATE | 0.6 mcg/kg every 2 weeks → 2× monthly once stable |
| Hgb < 7 g/dL or symptomatic | INITIATE + evaluate transfusion | Start ESA and assess need for red-cell transfusion in parallel |
Confirm adequate iron stores before the first ESA dose. Round computed doses to available vial strengths. Titrate toward the 10–11.5 g/dL target and do not adjust more often than every 4 weeks.
References
- Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group. KDIGO Clinical Practice Guideline for Anemia in Chronic Kidney Disease. Kidney Int Suppl. 2012;2(4):279–335.
- US Food and Drug Administration. Epoetin alfa (Epogen/Procrit) and Darbepoetin alfa (Aranesp) Prescribing Information — ESA REMS. Available at: fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/esa-apprise-oncology-program. Accessed 2026.
- Singh AK, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006;355(20):2085–2098. (CHOIR trial)
- Pfeffer MA, et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med. 2009;361(21):2019–2032. (TREAT trial)
- Methoxy polyethylene glycol-epoetin beta (Mircera) Prescribing Information. Genentech/Vifor. ESA-naïve correction starting dose 0.6 mcg/kg every 2 weeks. Accessed 2026.
- Epoetin beta (NeoRecormon) Summary of Product Characteristics. Subcutaneous correction-phase starting dose 20 IU/kg three times weekly. Accessed 2026.
